Literature DB >> 19255825

Aliskiren as an antiproteinuric add-on therapy in primary membranous nephropathy.

Ankur Gupta1,2, Ambar Khaira3, Bakshish Singh3, Dipankar M Bhowmik3, Suresh C Tiwari3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19255825     DOI： 10.1007/s10157-009-0130-5

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN： 1342-1751            Impact factor:   2.801


× No keyword cloud information.
  2 in total

Review 1.  Renin inhibition: what are the therapeutic opportunities?

Authors:  Naomi D L Fisher; Norman K Hollenberg
Journal:  J Am Soc Nephrol       Date:  2005-02-09       Impact factor: 10.121

2.  Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Authors:  Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg
Journal:  N Engl J Med       Date:  2008-06-05       Impact factor: 91.245
  2 in total
  2 in total

Review 1.  Direct inhibition of plasmatic renin activity with aliskiren: a promising but under-investigated therapeutic option for non-diabetic glomerulonephritis.

Authors:  Mariadelina Simeoni; Ramona Nicotera; Maria Colao; Maria Lucia Citraro; Elena Pelagi; Annamaria Cerantonio; Nicola Comi; Giuseppe Coppolino; Giorgio Fuiano
Journal:  Int Urol Nephrol       Date:  2015-10-05       Impact factor: 2.370

Review 2.  Direct renin inhibition in chronic kidney disease.

Authors:  Frederik Persson; Peter Rossing; Hans-Henrik Parving
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.